Core Insights - iBio, Inc. reported financial results for the second quarter ended December 31, 2024, highlighting advancements in its preclinical pipeline and corporate governance [1][4]. Corporate Developments - The company strengthened its leadership with key Board appointments, emphasizing its commitment to innovation and execution in developing next-generation therapeutics [2]. - iBio made significant progress in its preclinical pipeline, including the in-licensing of IBIO-600, a novel Activin E antibody discovery, and the initiation of a bispecific antibody program targeting myostatin/activin A [2][5]. Financial Performance - Revenue for the quarter was reported at $0.2 million, attributed to services provided to a collaborative partner [5]. - Research and Development (R&D) and General & Administrative (G&A) expenses totaled approximately $4.6 million, reflecting a slight increase of about 3% compared to the same period in fiscal 2024 [5]. - The net loss from continuing operations for the quarter was approximately $4.4 million, or $0.48 per share, compared to a net loss of approximately $4.5 million, or $2.42 per share, in the same period of fiscal 2024 [5]. Cash Position - As of December 31, 2024, the company reported cash, cash equivalents, and restricted cash of approximately $7.2 million, which includes $0.2 million of restricted cash [5].

Company Overview - iBio Inc is a biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other hard-to-treat diseases [1] - The company combines proprietary 3D modeling with innovative drug discovery platforms to create a pipeline of breakthrough antibody treatments [1] - iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine [1] Recent Developments - iBio announced the closing of a private placement offering with members of its Board of Directors and Officers, totaling over $650,000 [3] - The investments from the Board of Directors underscore their confidence and support in iBio's strategy to advance as a clinical-stage biotech focused on developing therapeutics for cardiometabolic diseases, obesity, and other challenging diseases [4] Pipeline and Technology - iBio is building an innovative pipeline of therapeutics in cardiometabolic disease and obesity that aims to promote healthy weight loss [6] - The company's breakthrough antibody treatments are designed to reduce obesity while preserving muscle mass, promoting muscle growth, and preventing weight regain [6] - iBio's machine-learning-based drug discovery platform is driving the development of these candidates, which are being engineered for high developability and an extended half-life potentially enabling reduced dosing than current obesity therapeutics [6] Forward-Looking Statements - The press release contains forward-looking statements regarding iBio's innovative pipeline of therapeutics in cardiometabolic disease and obesity, including their potential to promote healthy weight loss and address significant unmet medical needs [5] - These statements are based on current estimates and assumptions and are subject to various risks and uncertainties [5]

Core Insights - iBio, Inc. has successfully closed a private placement offering totaling over $650,000 with its Board of Directors and Officers, indicating strong internal support for the company's strategic direction [1][2] Company Overview - iBio is an AI-driven biotech company focused on developing precision antibody immunotherapies for cardiometabolic diseases, obesity, cancer, and other challenging diseases [4] - The company utilizes advanced computational biology and proprietary 3D modeling to create a pipeline of innovative therapeutics aimed at addressing significant unmet medical needs [4] Product Pipeline - iBio is developing a pipeline of therapeutics specifically targeting cardiometabolic diseases and obesity, with a focus on promoting healthy weight loss [3] - The antibody treatments are designed to reduce obesity while preserving muscle mass, promoting muscle growth, and preventing weight regain [3] - The company's machine-learning-based drug discovery platform is aimed at creating candidates with high developability and an extended half-life, potentially allowing for reduced dosing compared to current obesity therapeutics [3]

Core Insights - iBio, Inc. has developed an antibody that inhibits Activin E, a significant therapeutic target for cardiometabolic disorders and obesity, showcasing the potential of its AI-driven drug discovery platform [1][2][3] - The achievement is considered an industry first and strengthens iBio's pipeline for innovative therapeutics aimed at addressing high unmet medical needs in cardiometabolic health [2][4] Company Developments - iBio's Machine-Learning Antibody Engine successfully identified five critical epitope regions on the Activin E protein, enabling the development of synthetic epitopes and antibodies without the need to produce Activin E itself [2][3] - Preclinical studies indicate strong antibody binding to Activin E, demonstrating sub-nanomolar kinetics and complete blockade of its signaling in human adipocytes, which is crucial for metabolic health [3] - iBio has entered a collaboration with AstralBio, granting AstralBio an exclusive license to engineer four targets for cardiometabolic disease, while iBio retains the option to license three targets from AstralBio [4][5] Industry Context - Activin E is supported as a promising therapeutic target based on human genetics, with individuals having a protective mutation in the INHBE gene showing a healthier cardiometabolic profile [2] - The current GLP-1 class of therapeutics has limitations, highlighting the need for next-generation solutions that can effectively address obesity and its associated health risks [3] - The collaboration between iBio and AstralBio aims to accelerate the development of novel therapeutics for cardiometabolic diseases, leveraging advanced technology for rapid progress [5][6]

Financial Results Announcement - iBio, Inc. announced its financial results for the quarter ended September 30, 2024[4]. - The press release detailing the financial results was issued on November 12, 2024[4]. Company Information - The company is listed on NYSE American under the trading symbol IBIO[2]. - iBio, Inc. is not classified as an emerging growth company[3]. Regulatory Information - The financial information provided is not deemed "filed" under the Securities Exchange Act of 1934[5]. - The report was signed by Marc A. Banjak, Chief Legal Officer of iBio, Inc.[7].

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. “In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring ...

Financial Performance - Revenues for the fiscal year ended June 30, 2024, were approximately $0.225 million, a 100% increase compared to fiscal 2023[7] - iBio's consolidated net loss for the fiscal year ended June 30, 2024, was $24.9 million, a decrease of $40.1 million compared to 2023, primarily due to reduced expenses from discontinued operations and cost-saving initiatives[8] Expenses and Cost Management - Research and development expenses decreased by $5.1 million to $5.185 million, while general and administrative expenses decreased by $7.3 million to $11.674 million compared to fiscal 2023[8] - The company eliminated approximately $13.2 million in secured debt from its balance sheet by selling its manufacturing facility for $8.5 million and satisfying all obligations related to the debt[6] Financing Activities - iBio closed a public offering in the fiscal second quarter for gross proceeds of approximately $4.5 million and a private investment in public equity financing in the fiscal fourth quarter for gross proceeds of approximately $15.0 million[5] - The company strengthened its cash position by approximately $4.5 million from previously issued warrants during the third and fourth quarters[6] Cash and Assets - iBio's cash, cash equivalents, and restricted cash totaled $14.4 million as of June 30, 2024[8] - Cash and cash equivalents increased significantly from $4,301,000 in June 30, 2023 to $14,210,000 in June 30, 2024, marking an increase of over 230%[13] - Total current assets decreased from $26,259,000 in June 30, 2023 to $15,672,000 in June 30, 2024, representing a decline of approximately 40%[13] - The total assets decreased from $41,207,000 in June 30, 2023 to $28,734,000 in June 30, 2024, a decline of approximately 30%[13] Liabilities and Equity - Total liabilities decreased from $25,826,000 in June 30, 2023 to $7,410,000 in June 30, 2024, a reduction of approximately 71%[13] - Stockholders' equity increased from $15,381,000 in June 30, 2023 to $21,324,000 in June 30, 2024, reflecting an increase of about 38%[14] - The accumulated deficit widened from $(288,940,000) in June 30, 2023 to $(313,847,000) in June 30, 2024, indicating a decrease in retained earnings[14] - Additional paid-in capital rose from $304,320,000 in June 30, 2023 to $335,162,000 in June 30, 2024, an increase of approximately 10%[14] Shareholder Information - The number of common shares issued and outstanding increased from 1,015,505 to 8,623,676 between June 30, 2023 and June 30, 2024[14] Current Liabilities - Current liabilities related to assets held for sale decreased from $1,941,000 in June 30, 2023 to $0 in June 30, 2024[13] - The finance lease obligations - net of current portion decreased from $351,000 in June 30, 2023 to $53,000 in June 30, 2024, a reduction of about 85%[13] Clinical and Collaborative Developments - The company advanced a Trop2 x CD3 molecule to clinical candidate selection stage, demonstrating a significant 36% reduction in tumor size in a humanized mouse model[4] - iBio entered into a collaboration with AstralBio, Inc. to develop four targets in the cardiometabolic and obesity space, with rights to license up to three targets prior to clinical entry[4] Audit and Going Concern - The company received an audit opinion with a going concern paragraph, indicating substantial doubt about its ability to continue as a going concern[9]

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update. "Our fiscal year 2024 was a transformational year for iBio, as we've solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics," said CEO a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 13, 2024 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-35023 26-2797813 Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which | | --- ...